The company combines a strong scientific proposition with a relatively conservative financial structure. It has a differentiated, patented technology with early clinical and regulatory validation, including breakthrough designations and international approvals. On the financial side, high liquidity, low net debt, and a solid equity base give it room to continue funding R&D, building manufacturing capacity, and navigating the long path to commercialization.

Major risks center on execution and financing. There is still no revenue, losses are substantial, and free cash flow is deeply negative, so the business depends on ongoing access to external capital. Clinical and regulatory outcomes remain uncertain, and the company is highly concentrated in one core technology within an intensely competitive oncology landscape. Delays, disappointing data, or slower‑than‑expected adoption could pressure both the balance sheet and future fund‑raising.

In the near to medium term, the financials are likely to remain dominated by cash burn and external financing while the company works through pivotal trials, regulatory submissions, and early commercial launches. Successful milestones—such as positive pivotal data, additional approvals, and a ramp‑up in manufacturing and physician adoption—could eventually shift the story toward revenue growth and margin improvement. The overall outlook is high‑risk and milestone‑driven, with outcomes heavily dependent on clinical success, regulatory decisions, and the company’s ability to turn a strong scientific concept into a scalable, widely adopted cancer treatment.